A5031708261- Hedgehog Signaling Pathway Studies
- Nonmelanoma Skin Cancer Studies
- Skin and Cellular Biology Research
- Cutaneous Melanoma Detection and Management
- Cancer and Skin Lesions
- Skin Protection and Aging
- Autoimmune Bullous Skin Diseases
- Genetic and rare skin diseases.
- Vitamin D Research Studies
- Silk-based biomaterials and applications
- Dermatological and Skeletal Disorders
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Tumors and Oncological Cases
- Acne and Rosacea Treatments and Effects
- Dermatology and Skin Diseases
- melanin and skin pigmentation
- Lipoproteins and Cardiovascular Health
- Nail Diseases and Treatments
- Inflammatory mediators and NSAID effects
- Cutaneous lymphoproliferative disorders research
- Melanoma and MAPK Pathways
- Hair Growth and Disorders
- Cancer-related Molecular Pathways
- Immunotherapy and Immune Responses
Stanford University
2016-2025
Stanford Medicine
2010-2024
Palo Alto University
2019-2024
Nanjing Medical University
2024
Stanford Health Care
2023
Union Hospital
2023
Huazhong University of Science and Technology
2023
University of Washington
2022
Seattle University
2022
Clinique Saint Jean
2017
Dysregulated hedgehog signaling is the pivotal molecular abnormality underlying basal-cell carcinomas. Vismodegib a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic carcinomas.We tested anti-basal-cell carcinoma efficacy of vismodegib randomized, double-blind, placebo-controlled trial patients with nevus syndrome at three clinical centers from September 2009 through January 2011. The primary end point was reduction...
Itraconazole, a US Food and Drug Administration-approved antifungal drug, inhibits the Hedgehog (HH) signaling pathway, crucial driver of basal cell carcinoma (BCC) tumorigenesis, reduces BCC growth in mice. We assessed effect itraconazole on HH pathway tumor size human tumors.Patients with ≥ one > 4 mm diameter were enrolled onto two cohorts to receive oral 200 mg twice per day for 1 month (cohort A) or 100 an average 2.3 months B). The primary end point was change biomarkers: Ki67...
<h3>Importance</h3> Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating, often fatal, inherited blistering disorder caused by mutations in the<i>COL7A1</i>gene encoding type VII collagen. Support and palliation are the only current therapies. <h3>Objective</h3> To evaluate safety wound outcomes following genetically corrected autologous epidermal grafts patients with RDEB. <h3>Design, Setting, Participants</h3> Single-center phase 1 clinical trial conducted United States of 4...
Abstract Cutaneous squamous cell carcinoma represents the second most common cutaneous malignancy, affecting 7–11% of Caucasians in United States. The genetic determinants susceptibility to remain largely unknown. Here we report results a two-stage genome-wide association study carcinoma, totalling 7,404 cases and 292,076 controls. Eleven loci reached significance ( P <5 × 10 −8 ) including seven previously confirmed pigmentation-related loci: MC1R , ASIP TYR SLC45A2 OCA2 IRF4 BNC2 . We...
Abstract Constitutive Hedgehog (HH) signaling underlies several human tumors, including basal cell carcinoma (BCC). Recently, Bijlsma and colleagues reported a new biologic function for vitamin D3 in suppressing HH an vitro model system. On the basis of that work, we have assessed effects on proliferation murine BCCs vivo. We find indeed BCC cells, blocks both as by mRNA expression target gene Gli1. These Gli1 are comparable to cyclopamine, known inhibitor pathway. results specific D3,...
BackgroundThe substance P/neurokinin 1 receptor pathway is critical in chronic pruritus; anecdotal evidence suggests that antagonism of this can reduce itch.ObjectiveTo assess the safety and efficacy antagonist serlopitant treating pruritus.MethodsEligible patients with severe pruritus who were refractory to antihistamines or topical steroids randomized serlopitant, 0.25, 1, 5 mg, placebo, administered once daily for 6 weeks as monotherapy midpotency emollients. The primary end point was...
Abstract Basal cell carcinoma (BCC) is the most common cancer worldwide with an annual incidence of 2.8 million cases in United States alone. Previous studies have demonstrated association between 21 distinct genetic loci and BCC risk. Here, we report results a two-stage genome-wide study BCC, totalling 17,187 287,054 controls. We confirm 17 previously reported identify 14 new susceptibility reaching significance ( P <5 × 10 −8 , logistic regression). These newly associated SNPs lie...
BACKGROUND. Recessive dystrophic epidermolysis bullosa (RDEB) patients have mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they marked skin fragility blistering. This single-center phase 1/2a open-label study evaluated long-term efficacy, safety, patient-reported outcomes RDEB treated with gene-corrected autologous cell therapy.
Tumor resistance is an emerging problem for Smoothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC). Arsenic trioxide and itraconazole antagonize the hedgehog (HH) pathway at sites distinct from those treated by SMO inhibitors.To determine whether administration of intravenous arsenic oral in patients with BCC associated a reduction GLI1 messenger RNA expression tumor and/or normal skin biopsy samples.Five men who experienced relapse after inhibitor treatment underwent 5...
Abstract Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic disorder due to pathogenic variants in the COL7A1 gene. In this study we determined association between different categories of and clinical disease severity 236 RDEB patients North America. Published reports or in-silico predictions were used assess impact on type VII collagen (C7) protein function. Three postulated: genotypes that would likely cause low C7 function (splice B/missense, missense/missense), medium...
In light of inverse relationships reported in observational studies vitamin D intake and serum 25-hydroxyvitamin levels with risk nonmelanoma skin cancer (NMSC) melanoma, we evaluated the effects combined calcium supplementation on a randomized placebo-controlled trial.Postmenopausal women age 50 to 79 years (N = 36,282) enrolled onto Women's Health Initiative (WHI) calcium/vitamin clinical trial were randomly assigned receive 1,000 mg elemental plus 400 IU D3 (CaD) daily or placebo for mean...